An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Latest Information Update: 08 Jul 2024
At a glance
- Drugs GEN 3014 (Primary) ; Daratumumab
- Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Genmab A/S
- 12 Jan 2024 Planned End Date changed from 1 Feb 2029 to 31 Dec 2026.
- 12 Dec 2023 Results (N=11, As of May 5, 2023, median age, 66 years; range, 56-75 ) assessing the preliminary antitumor activity, safety, tolerability, and pharmacokinetics/pharmacodynamics of GEN3014 were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 02 Nov 2023 According to a Genmab media release, data from this study will be presented at the 65thAnnual Meeting and Exposition of the American Society of Hematology (ASH)